Assessment of our Corporate Sustainability is often driven by a need to
comply in order to achieve the tick in a box for tender activity but is this
how it should be perceived?
Surely implemented in the right spirit and with across the board buy-in, this
buzz word strategy is a strong driver to business growth potential if only by
spreading the word throughout your sector that you are sustainably aware and
striving to be the best you can in your environment.
Didn't Marks and Spencer role out Plan A? A 5 year road map to spend £200
Million improving their sustainability by 2012? Within 2 years they announced
they were ‘cost positive' for the project,generating returns as early as
Very few organisations perceive sustainability as an opportunity to drive up
the bottom line, but history proves this to be an outcome of investment in
positioning yourself as a leade... (more)
John Funnel on Ulitzer
Earlier this year one of my staff attended a SYS-CON event and returned to
the office a different person. Revitalised and motivated.
I asked her what happened at the event to warrant such a transformation? What
was her secret? Was it the New York Shopping experience? A business Romance
or was it Devine intervention?
She simply advised me to ‘check out Ulitzer. – Everyone who is anyone is
She was not the first to introduce me to the innovation. Many of my peers had
gone through such noticeable changes, It was like a weight had been lifted
from the... (more)
Green Technology Journal on Ulitzer
The week that Coca Cola’s staff are sporting uniforms made from recycled
bottles at the Vancouver 2010 Olympics, Esat Sezer, CIO of Coca Cola
Enterprises, explains candidly to meettheboss.tv how going Green is more than
just a Corporate responsibility.
Esat Sezer is the current SVP and CIO with Coca Cola Enterprises and has been
working with them since 2006. The Challenge with Green IT, is to take the
buzz that has been created around the recent phenomenon and mobilizing it
into effective strategies for growth and efficiency.
Esat explains “I... (more)
Large pharma has been seeking new biomarkers for years - all part of their
drug discovery process, but often only as an afterthought in the development
process. That's changed over recent years, but by-and-large the bulk of
biomarker work remains in the hands of small -to -medium-sized companies
whose focused approach is more attuned to biomarkers being a major element of
a final product.
Pharmaceutical companies have invested heavily in Translational Science (TS),
both clinical and pre-clinical, to smooth the passage of compounds into
clinical development. There are some excell... (more)
The economic crisis of 2009 presented a false base for many businesses
including ours, giving us nothing upon which to produce any meaningful type
of growth statistics or trend data but all things considered our result of
400% is still incredible growth by any standards. So in this environment and
at these high levels of growth how can you possibly manage costs based on
historical information or results? Well the fact is you can't!
After many years, I am now of the view that there are two sides to finance,
the ‘science' and the ‘art'. Drawing upon a flying analogy, the numbers